Hepatocellular carcinoma
Conditions
Interventions
Sponsors
Nanjing Drum Tower Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Female or male aged 18 to 75 years; 2. Histologic or cytologic confirmation of advanced hepatocellular carcinoma; 3. Patients without measurable lesions after surgery, and stage II-III (AJCC 7th); 4. Child-pugh A-B; 5. ECOG<0-2; 6. Patients had not received systemic venous chemotherapy ever before; 7. Hematology Index; 8. Neutrophile granulocyte greater than 1.5×10^9/L; 9. Hemoglobin greater than 10g/dL; 10. Platelet greater than 90×10^9/L; 11. Biochemical index; 12. Serum bilirubin not greater than 1.5x upper limit of reference range (ULN); 13. ALT or AST not greater than 1.5x ULN; 14. Creatinine clearance no less than 60ml/min; 15. Negative pregnancy test for women of childbearing potential; 16. Provision of informed consent; 17. Be able to follow the research program and follow up process; 18. Expected survival time 3 months or more.
Exclusion criteria
Exclusion criteria: 1. Chemotherapy with experimental drug within 3 months before the start of study therapy; 2. Have at least another primary malignant tumor; 3. Active infection with bacterial or fungal infection; 4. Patients with HIV infection, HCV infection, serious coronary artery disease or asthma, serious cerebrovascular disease or other diseases that the researchers think can not be entered into the group; 5. Women who are pregnant or breast feeding; 6. Drug abuse, clinical or psychological or social factors which will influence the informed consent or the study implementation; 7. May be allergic to immunotherapy; 8. Radiotherapy and immunotherapy may not be implemented due to social or geographical factors; 9. Weight loss greater 10% within 6 weeks before the start of study therapy; 10. influence the safety or compliance of the patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DFS;Immune index; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;safety;Tumor marker; | — |
Countries
China
Contacts
Public ContactBaorui Liu
The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital
Outcome results
None listed